|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chronic HCV infection and inflammation:Clinical impact on hepatic and extra-hepatic manifestations显示文摘The liver has a central role in regulating inflammation by its capacity to secrete a number of proteins that control both local and systemic inflammatory responses. Chronic inflammation or an exaggerated inflammatory response can produce detrimental effects on target organs. Chronic hepatitis C virus(HCV) infection causes liver inflammation by complex and not yet well-understood molecular pathways, including direct viral effects and indirect mechanisms involving cytokine pathways,oxidative stress and steatosis induction. An increasing body of evidence recognizes the inflammatory response in chronic hepatitis C as pathogenically linked to the development of both liver-limited injury(fibrosis, cirrhosis and hepatocellular carcinoma) and extrahepatic HCV-related diseases(lymphoproliferative disease,atherosclerosis, cardiovascular and brain disease). Defining the complex mechanisms of HCV-induced inflammation could be crucial to determine the global impact of infection, to estimate progression of the disease, and to explore novel therapeutic approaches to avert HCVrelated diseases. This review focuses on HCV-related clinical conditions as a result of chronic liver and systemic inflammatory states. | Rosa Zampino Aldo Marrone Luciano Restivo Barbara Guerrera Ausilia Sellitto Luca Rinaldi Ciro Romano Luigi E Adinolfi | 2013 | World Journal of Hepatology2013，5，10： | 13 |
| 2 | Chronic hepatitis C virus infection and neurological and psychiatric disorders:An overview显示文摘Hepatitis C virus(HCV)infection is considered a systemic disease because of involvement of other organs and tissues concomitantly with liver disease.Among the extrahepatic manifestations,neuropsychiatric disorders have been reported in up to 50%of chronic HCV infected patients.Both the central and peripheral nervous system may be involved with a wide variety of clinical manifestations.Main HCV-associated neurological conditions include cerebrovascular events,encephalopathy,myelitis,encephalomyelitis,and cognitive impairment,whereas'brain fog',depression,anxiety,and fatigue are at the top of the list of psychiatric disorders.Moreover,HCV infection is known to cause both motor and sensory peripheral neuropathy in the context of mixed cryoglobulinemia,and has also been recently recognized as an independent risk factor for stroke.These extrahepatic manifestations are independent of severity of the underlying chronic liver disease and hepatic encephalopathy.The brain is a suitable site for HCV replication,where the virus may directly exert neurotoxicity;other mechanisms proposed to explain the pathogenesis of neuropsychiatric disorders in chronic HCV infection include derangement of metabolic pathways of infected cells,alterations in neurotransmitter circuits,autoimmune disorders,and cerebral or systemic inflammation.A pathogenic role for HCV is also suggested by improvement of neurological and psychiatric symptoms in patients achieving a sustained virologic response following interferon treatment;however,further ad hoc trials are needed to fully assess the impact of HCV infection and specific antiviral treatments on associated neuropsychiatric disorders. | Luigi Elio Adinolfi Riccardo Nevola Giacomo Lus Luciano Restivo Barbara Guerrera Ciro Romano Rosa Zampino Luca Rinaldi Ausilia Sellitto Mauro Giordano Aldo Marrone | 2015 | World Journal of Gastroenterology2015，21，8： | 6 |
| 3 | Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms显示文摘Hepatitis C virus(HCV)infection represents a major health issue worldwide due to its burden of chronic liver disease and extrahepatic manifestations including cardiovascular diseases,which are associated with excess mortality.Analysis of published studies supports the view that HCV infection should be considered a risk factor for the development of carotid atherosclerosis,heart failure and stroke.In contrast,findings from studies addressing coronary artery disease and HCV have yielded conflicting results.Therefore,meta-analytic reviews and prospective studies are warranted.The pathogenic mechanisms connecting HCV infection,chronic liver disease,and atherogenesis are not completely understood.However,it has been hypothesized that HCV may promote atherogenesis and its complications through several direct and indirect biological mechanisms involving HCV colonization and replication within arterial walls,liver steatosis and fibrosis,enhanced and imbalanced secretion of inflammatory cytokines,oxidative stress,endotoxemia,mixed cryoglobulinemia,perturbed cellular and humoral immunity,hyperhomocysteinemia,hypo-adiponectinaemia,insulin resistance,type 2 diabetes and other components of the metabolic syndrome.Understanding these complex mechanisms is of fundamental importance for the development of novel therapeutic approaches to prevent and to treat vascular complications in patients with chronic HCV infection.Currently,it seems that HCV clearance by interferon and ribavirin treatment significantly reduces non-liver-related mortality;moreover,interferon-based treatment appears to decrease the risk of ischemic stroke. | Luigi E Adinolfi Rosa Zampino Luciano Restivo Amedeo Lonardo Barbara Guerrera Aldo Marrone Fabio Nascimbeni Anna Florio Paola Loria | 2014 | World Journal of Gastroenterology2014，20，13： | 6 |
| 4 | Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis显示文摘AIM To characterize natural history of cryptogenic cirrhosis(CC) and compare its clinical features and outcomes to those of hepatitis C virus(HCV)-related cirrhosis.METHODS A prospective cohort of 102 consecutive patients at their first diagnosis of CC were enrolled in this study. The clinical data and outcomes were compared to an ageand Child-pugh class-matched cohort of 110 patients with HCV-related cirrhosis. Diagnosis of cirrhosis was based on compatible clinical and laboratory parameters, ultrasound/endoscopic parameters and, whenever possible, on histological grounds and transient elastography. All cases of cirrhosis without a definite etiology were enrolled in the CC group. The parameters assessed were:(1) severity of liver disease at the time of first diagnosis;(2) liver decompensation during follow-up;(3) hepatocellular carcinoma(HCC);(4) orthotopic liver transplantation; and(5) death. The independent associated factors were evaluated by multiple logistic regression analysis, and survival and its determinants by the Kaplan-Meier model, log-rank test and Cox regression.RESULTS At the first observation, median age was 66 and 65 years and male gender was 36% and 58% for CC and HCV cirrhosis, respectively. CC showed Child-pugh class A/B/C of 47%/31%/22%, respectively. Compared to HCV cirrhosis, CC exhibited a significantly higher prevalence of metabolic syndrome(12% vs 54%, respectively), overweight/obesity, high BMI, impaired glucose tolerance, high blood pressure, dyslipidemia, hyperuricemia, cardiovascular diseases, extrahepatic cancer, and gallstones. Over a median period of 42 mo of follow-up, liver decompensation, HCC development and death for CC and HCV-related cirrhosis were 60.8%, and 54.4%, 16.7% and 17.2%, 39.2% and 30%, respectively. The median survival was 60 mo for CC. Independent predictors of death were age and Childpugh class at diagnosis. CC showed an approximately twofold higher incidence of HCC in Child-pugh class A.CONCLUSION Undiagnosed nonalcoholic fatty liver disease has an etiologic role in CC that is associated with a poor prognosis, early HCC development, high risk of cardiovascular disease and extrahepatic cancer. | Luca Rinaldi Fabio Nascimbeni Mauro Giordano Chiara Masetti Barbara Guerrera Annalisa Amelia Maria Chiara Fascione Stefano Ballestri Dante Romagnoli Rosa Zampino Riccardo Nevola Enrica Baldelli Natalina Iuliano Valerio Rosato Amedeo Lonardo Luigi Elio Adinolfi | 2017 | World Journal of Gastroenterology2017，23，8： | 5 |
| 5 | Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis显示文摘 | Luigi E. Adinolfi Luciano Restivo Rosa Zampino Barbara Guerrera Amedeo Lonardo Laura Ruggiero Francesco Riello Paola Loria Anna Florio | 2012 | Atherosclerosis2012，，2： | 3 |
| 6 | Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis显示文摘 | Luigi E. Adinolfi Luciano Restivo Rosa Zampino Barbara Guerrera Amedeo Lonardo Laura Ruggiero Francesco Riello Paola Loria Anna Florio | 2012 | Atherosclerosis2012，，2： | 2 |
| 7 | A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients 显示文摘 | Guerrera I C Astarita G Jais J P | 2009 | PloS One2009，4，11： | 1 |
| 8 | Morphology of the tongue dorsal surface of gilthead seabream ( Sparus aurata )显示文摘 | F. Abbate M.C. Guerrera G. Montalbano E. Ciriaco A. Germanà | 2012 | Microsc Res Tech2012，，12： | 1 |
| 9 | All-oral interferon-free treatments:The end of hepatitis C virus story,the dream and the reality显示文摘The year 2014 marked the beginning of the end of the interferon era and the triumph of the all-oral interferon-free regimens for treatment of hepatitis C virus(HCV) infection. These innovative therapies are safe and yield a cure rate of over 90%. The scientifichepatology community is euphoric about the possibility of elimination and even eradication of HCV infection. However,the current high cost of the new all-oral regimens allows access to treatment only for a restricted number of HCV-infected patients. In addition,many other conditions such as modality of access and delivery of care,inadequate knowledge of HCV epidemiology and political commitments to be undertaken,hamper the fulfillment of the dream to eliminate the virus. Since,such conditions are not impossible to overcome,a global urgent effort must be made to allow a widespread access to the new treatments which will permit in the next years to avoid million of HCV-related deaths. | Luigi E Adinolfi Barbara Guerrera | 2015 | World Journal of Hepatology2015，7，22： | 1 |
| 10 | Does the World Health Organization histological classification predict outcomes after thymomectomy? Results of a multicentre study on 750 patients 显示文摘 | Guerrera F Rendina EA Venuta F | 2014 | Eur J Cardiothorac Surg2014，，： | 1 |
| 11 | Ganglioside GDla enhances VEGF-induced endothelial cell proliferation and mi- gration 显示文摘 | LANG Z GUERRERA M LI R | 2001 | Biochem Biophys Res Commun2001，，282： | 1 |
| 12 | Ambulatory blood pressure and cardiac rhythm disturbances in elderly hypertensives:Relation to left ventricular mass and filling pattern显示文摘 | COLIVICCHI F GUERRERA C MELINA G | 1996 | Age Aging1996，25，： | 1 |
| 13 | Application of mass spectrometry in proteomics 显示文摘 | Ida Chiara Guerrera Oliver Kleiner | 2005 | Bioscience Reports2005，25，1： | 1 |
| 14 | A prospective study of local recurrence after resection and low stapled anastomosis in 183 patients with rectal cancer显示文摘 | Vettorello GF Guerrera C | 1990 | Dis Colon Rectum1990，33，2： | 1 |
| 15 | Efficient confocal microscopy with a dual-wedge scanner 显示文摘 | WILLIAM C WARGER I I GUERRERA S A | 2009 | SPIE2009，7184，： | 1 |
| 16 | S100 expression in the lateral line system of zebra fish from juvenile to adult stages显示文摘 | German-t A Abbate F Guerrera M | 2005 | Anatomia Histologia Embryohigia2005，34，： | 1 |
| 17 | 1037 HCV INFECTION IMPAIRS GLUCOSE METABOLISM WHICH PROMOTES A MORE AGGRESSIVE COURSE OF LIVER DISEASE AND METABOLIC SYNDROME显示文摘 | L.E. Adinolfi R. Zampino L. Restivo B. Guerrera A. Santoro A. Ciervo L. Rinaldi V.R. Scialdone M. Ferrara G. Ruggiero | 2010 | Journal of Hepatology2010，，： | 1 |
| 18 | Extended transcervical thymectomy with partial upper sternotomy: results in non tbymomatous patients with myasthenia gravis 显示文摘 | Ruffini E Guerrera F Filosso PL | 2015 | Eur J Cardiothorac Surg2015，48，3： | 1 |
| 19 | Expression and cell localization of brain-derived neurotrophic factor and TrkB during zebrafish retinal development显示文摘 | Germanà A Sánchez-Ramos C Guerrera MC Calavia MG Navarro M Zichichi R | | 0，，3： | 1 |
| 20 | Steatosis is the predictor of relapse in HCV genotype 3-but not 2-infected patients treated with 12weeks of pegylated interferon-α-2aplus ribavirin and RVR显示文摘 | Restivo L Zampino R Guerrera B | 2012 | J Viral Hepat2012，19，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员